X

Trial Profile

A phase Ib study assessing GB491 and Fulvestrant in second line HR+/HER2- advanced breast cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Lerociclib (Primary)
Indications Advanced breast cancer
Focus Adverse reactions
Sponsors Genor Biopharma

Most Recent Events

12 Apr 2021 New trial record
08 Mar 2021 According to a Genor Biopharma media release, as of 6th March 2021, the ethical approval for this trial was obtained.
08 Mar 2021 According to a Genor Biopharma media release, the company announced that it has received investigational new drug (IND) approvals from the National Medical Products Administration (NMPA) to begin this bridging study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com